SRNE - First patient enrolled in China Oncology's late-stage socazolimab lung cancer trial

China Oncology Focus has enrolled the first patient in China in the late-stage trial of socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer ((ES-SCLC)). China Oncology had received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan, from Sorrento ([[SRNE]] -4.8%).Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.The initiation of the trial is based on results from an earlier Phase Ib trial in which socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with ES-SCLC, the company said.Socazolimab had won China's NMPA breakthrough therapy status, in February.

For further details see:

First patient enrolled in China Oncology's late-stage socazolimab lung cancer trial